# Bioequivalence Study of Dronedarone Hydrochloride Tablets

> **NCT07396519** · NA · COMPLETED · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 48 (actual)

## Conditions studied

- Atrial Fibrillation (AF)

## Interventions

- **DRUG:** Dronedarone Hydrochloride Tablets
- **DRUG:** MULTAQ® (Dronedarone Hydrochloride Tablets)

## Key facts

- **NCT ID:** NCT07396519
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-14
- **Primary completion:** 2022-12-07
- **Final completion:** 2022-12-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07396519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07396519, "Bioequivalence Study of Dronedarone Hydrochloride Tablets". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07396519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*